Clinical Utility of Serum Cystatin C in Predicting Coronary Artery Disease in Patients Without Chronic Kidney Disease

• Published in: Journal of clinical laboratory analysis Vol. 28; no. 3; pp. 191 - 197
• Main Authors: Dandana, Azza, Gammoudi, Imen, Chalghoum, Abdelkader, Chahed, Hinda, Addad, Faouzi, Ferchichi, Salima, Miled, Abdelhedi
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.05.2014; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: biochemical atherosclerosis markers; Biochemistry; Biomarkers; Biomarkers - blood; C-Reactive Protein - metabolism; Cardiovascular disease; coronary artery disease; Coronary Artery Disease - blood; Coronary Artery Disease - complications; cystatin C; Cystatin C - blood; Estimated glomerular filtration rate; Female; Glomerular Filtration Rate; Humans; Lipoproteins, HDL; Logistic Models; Male; Multivariate Analysis; Renal Insufficiency, Chronic - blood; Risk Factors; coronary artery disease; cystatin C; biochemical atherosclerosis markers; Estimated glomerular filtration rate
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.21665

Background Cystatin C has been proposed as a novel marker of renal function and predictor of cardiovascular risk. The aim of this study was to investigate the role of cystatin C level as a predictor of cardiovascular events in patients with coronary artery disease (CAD). Methods Three hundred and five coronary artery patients were included in this study. Serum cystatin C levels, high‐sensitive C‐reactive protein (hs‐CRP), and oxidative stress were measured. Estimated glomerular filtration rate (eGFR) and the CAD severity score were calculated. Results Cystatin C was correlated with the CAD severity score (r = 0.631, P < 0.0001) and was significantly elevated in the CAD severity score >50. Every 0.1 mg/l increase in cystatin C, 2 mg/l increase in hs‐CRP, 0.2 mmol/l decrease in high‐density lipoprotein cholesterol, 13.7 ml/min decrease in eGFR, and 1.51 μmol/l increase in homocysteine caused a 34, 12, 5, and 22% increase in the risk of having CAD, respectively. Conclusion Cystatin C could be a useful laboratory biochemical marker in predicting the severity of CAD. Cystatin C is associated with biochemical atherosclerosis markers such as CRP and homocysteine.